<DOC>
	<DOCNO>NCT00744679</DOCNO>
	<brief_summary>The primary objective ass pharmacokinetic ( PK ) profile natalizumab ( Tysabri ) steady state . The secondary objective ass pharmacodynamics ( PD ) profile ( α4 integrin saturation ) Tysabri steady state .</brief_summary>
	<brief_title>A Pharmacokinetic ( PK ) Study Natalizumab ( Tysabri ) Steady State</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) accordance national local subject privacy regulation . Must multiple sclerosis ( MS ) patient enrol Tysabri Outreach : United Commitment Health Prescribing Program ( TOUCH ) expect discontinue Tysabri therapy prior completion requirement study . Must treat monthly IV infusion Tysabri 300 mg least 12 month , 9 recent dos administer 28±7 day interval . Must test negative antibody Tysabri Screening Visit . Must magnetic resonance imaging ( MRI ) brain scan , perform prior initiation treatment Tysabri , file . Must weigh 42 126 kg , inclusive . All male subject female subject childbearing potential must practice effective contraception study . Key History , abnormal laboratory result indicative , clinically significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , gastrointestinal , dermatologic , psychiatric , renal , major disease , determine Investigator . Positive result antibody Tysabri prior evaluation . Treatment investigational product approve therapy investigational use within 6 month prior start PK sample collection course study . Concurrent participation observational study ( e.g. , Tysabri Global Observational Program Safety [ TYGRIS ] ) permit . Prescheduled elective procedure medical treatment study period . History drug alcohol abuse ( define Investigator ) within 2 year prior Screening Visit . Female subject breastfeeding , pregnant , plan become pregnant study . Alcohol use within 24 hour prior Baseline Visit . Inability unwillingness comply study requirement , include presence condition ( e.g. , physical , mental , social ) likely affect subject 's ability comply study protocol . Other unspecified reason , opinion Investigator Biogen Idec , make subject unsuitable enrollment . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>MS</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>